Recruiting nowPhase 2Ages 18 Years and up

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Sponsor: Bayer · NCT06760819 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Advanced Solid TumorsHER2 Mutation

What it tests

BAY2927088drug

Where it's running54 sites

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
Birmingham, Alabama 35233
Recruiting now
City of Hope - Duarte Cancer Center
Duarte, California 91010
Recruiting now
Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus
Fort Myers, Florida 33908
Recruiting now
Dana-Farber Cancer Institute - Oncology Department
Boston, Massachusetts 02215
Recruiting now
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit
Detroit, Michigan 48202
Withdrawn
Profound Research -OMG - TriAtria Cancer Center
Farmington Hills, Michigan 48334
Recruiting now
Cleveland Clinic - Oncology Department
Cleveland, Ohio 44195
Recruiting now
SCRI Oncology Partners
Nashville, Tennessee 37203
Recruiting now
The University of Texas MD Anderson Cancer Center - Texas Medical Center
Houston, Texas 77030
Recruiting now
Gynecology Oncology clinic at UW Medical Center - Montlake
Seattle, Washington 98195
Withdrawn
UW Health Carbone Cancer Center
Madison, Wisconsin 53792
Recruiting now

43 international sites

NSW Health - Blacktown Hospital
Blacktown, New South Wales, Australia 2148
Recruiting now
Macquarie University Hospital - Oncology Department
Sydney, New South Wales, Australia 2109
Recruiting now
ICON Cancer Centre - Southport
Southport, Queensland, Australia 4215
Recruiting now
Queen Elizabeth II Health Sciences Centre | Oncology
Halifax, Nova Scotia, Canada B3H 2Y9
Recruiting now
Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology
Toronto, Ontario, Canada M5G 2C4
Recruiting now
McGill University Health Centre - Glen Site - Women Health's Research Unit
Montreal, Quebec, Canada H4A 3J1
Recruiting now
Peking University First Hospital - Oncology Department
Beijing, Beijing Municipality, China 100034
Recruiting now
Beijing Cancer Hospital - Oncology Department
Beijing, Beijing Municipality, China 100142
Recruiting now
Hunan Cancer Hospital - Oncology Department
Changsha, Hunan, China 410013
Recruiting now
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China 200032
Recruiting now
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, China 310016
Recruiting now
Fudan University Shanghai Cancer Center - Oncology Department
Shanghai, China 200000
Recruiting now
Rigshospitalet Copenhagen University Hospital | Oncology Department
Copenhagen, Capital Region, Denmark 2100
Recruiting now
Aarhus University Hospital | Oncology Department - Clinical Research Unit
Aarhus N, Central Jutland, Denmark 8200
Recruiting now
Odense University Hospital | Svendborg Sygehus - Oncology Department
Odense, Region Syddanmark, Denmark 5000
Recruiting now
Centre Hospitalier Lyon Sud - Service oncologie medicale
Pierre-Bénite, Auvergne-Rhône-Alpes, France 69310
Recruiting now
CHU Brest - Hopital La Cavale Blanche - service oncologie medicale
Brest, Brittany Region, France 29200
Recruiting now
Centre Oscar Lambret - Service Oncologie
Lille, Hauts-de-France, France 59000
Recruiting now
Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
Bordeaux, New Aquitaine, France 33000
Recruiting now
ICM - Institut du Cancer de Montpellier - Val d'Aurelle - CIPP
Montpellier, Occitanie, France 34298
Recruiting now
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)
Villejuif, Île-de-France Region, France 94805
Recruiting now
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
Milan, Italy 20133
Recruiting now
Istituto Europeo di Oncologia s.r.l - Ginecologia Oncologica Medica
Milan, Italy 20141
Recruiting now
Azienda USL IRCCS di Reggio Emilia_Arcispedale Santa Maria Nuova - S.C. Oncologia Provinciale
Reggio Emilia, Italy 42123
Recruiting now
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Roma, Italy 00168
Recruiting now
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, Japan 464-8681
Recruiting now
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus
Kashiwa, Chiba, Japan 277-8577
Recruiting now
Hokkaido University Hospital
Sapporo, Hokkaido, Japan 060-8648
Recruiting now
Kindai University Hospital
Sakai, Osaka, Japan 590-0197
Recruiting now
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan 104-0045
Recruiting now
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan 135-8550
Recruiting now
Severance Hospital, Yonsei University Health System - Oncology Department
Seoul, Seoul Teugbyeolsi, South Korea 03722
Recruiting now
Asan Medical Center | Oncology
Seoul, Seoul Teugbyeolsi, South Korea 05505
Recruiting now
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea 3080
Recruiting now
Samsung Medical Center - Oncology Department
Seoul, South Korea 06351
Recruiting now
Institut Catala D'oncologia | Hospitalet | Oncologia
L'Hospitalet de Llobregat, Barcelona, Spain 08908
Recruiting now
Clinica Universidad De Navarra | Madrid | Oncologia
Madrid, Navarre, Spain 28027
Recruiting now
Instituto Oncologico Dr. Rosell S.L. | Oncologia
Barcelona, Spain 08028
Recruiting now
Hospital Universitari Vall D Hebron | Oncologia Medica
Barcelona, Spain 08035
Recruiting now
Hospital Universitario Fundacion Jimenez Diaz | Oncologia Medica
Madrid, Spain 28040
Recruiting now
Inselspital Bern - Universitätsklinik für Medizinische Onkologie
Bern, Switzerland 3010
Recruiting now
Hopitaux Universitaires de Geneve - Oncology Department
Geneva, Switzerland 1205
Recruiting now
Univestitätsspital Zürich (USZ)
Zurich, Switzerland 8091
Recruiting now

See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; breast cancer; other solid tumor cancer, excluding NSCLC)
* Participant must be ≥18 years of age or over the legal age of consent
* Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments
* Documented activating HER2 mutation
* At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria

Exclusion Criteria:

* Primary diagnosis of non-small cell lung cancer (NSCLC)
* Prior treatment with a HER2 tyrosine kinase inhibitor (TKI)
* Active brain metastases
* Uncontrolled, severe, intercurrent illness

Updated 2026-06-04 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.